Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - crizotinib -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - crizotinib -

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

pfizer laboratories limited, kenya - crizotinib - capsules, hard - 200

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

pfizer laboratories limited, kenya - crizotinib - capsules, hard - 250

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - crizotinib 200mg;  ;   - capsule - 200 mg - active: crizotinib 200mg     excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - crizotinib 250mg;  ;   - capsule - 250 mg - active: crizotinib 250mg     excipient: calcium hydrogen phosphate colloidal silicon dioxide gelatin iron oxide red magnesium stearate microcrystalline cellulose sodium starch glycolate tekprint black sw-9008 titanium dioxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - crizotinib - capsule - 200 mg - crizotinib 200 mg

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - crizotinib - capsule - 250 mg - crizotinib 250 mg

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinoma, non-small-cell lung - antineoplastic agents - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to

Canada - English - Health Canada

pfizer canada ulc - crizotinib - capsule - 200mg - crizotinib 200mg - antineoplastic agents